| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","as_of":"2026-04-07T03:18:43.308311+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","article_chars":1756,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_3fcc77a692a443cd","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","content_type":"text/plain","enriched_at":"2026-04-07T08:19:49.886875+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","source_event_id":"evt_221dee25d80a","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"44d3be14fe614755","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-06"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"issuer","symbol":"TVTX","type":"company"}],"event_type":"listing","information_gaps":["No details on the financial implications of the stock option exercise are provided."],"key_facts":["Form 144 filed on April 6, 2026.","Director Roy Baynes exercised stock options for 10,000 shares.","The filing indicates a cash transaction."],"numeric_claims":[{"label":"Shares Exercised","value":"10,000"},{"label":"Transaction Date","value":"04/06/2026"}],"primary_claim":"Travere Therapeutics, Inc. filed Form 144 on April 6, 2026.","relevance_score":0.7,"sentiment":"neutral","source_quality":"medium","summary":"Travere Therapeutics, Inc. filed Form 144 on April 6, 2026, indicating a stock option exercise by Director Roy Baynes.","topics":["SEC Filing","Stock Option Exercise"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260406","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 144","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt"}... |